Mylan Receives EU Marketing Approval for Adalimumab Biosimilar “Hulio”

 Mylan Receives EU Marketing Approval for Adalimumab Biosimilar “Hulio”

Mylan Receives EU Marketing Approval for Adalimumab Biosimilar “Hulio”

Shots:

  • Hulio’s EU Marketing Approval is followed after CHMP approval that demonstrated analytical, functional, clinical and immunogenicity data similar to AbbVie’s Humira
  • In 2018, Kyowa and Mylan signed an agreement for exclusive commercialization right of Hulio in EU, and is expect to launch on or after 16 Oct, 2018
  • Adalimumab is an injectable, biologic medication inhibits Tumour Necrosis Factor (TNF), which is indicated for autoimmune diseases such as rheumatoid arthritis, plaque psoriasis, crohn’s disease and ulcerative colitis

Click here to read full press release/ article | Ref: Mylan | Image: Pittsburgh Post-Gazette

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post